person · Reporting owner
Jansen Valerie Malyvanh
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elevation Oncology, Inc.ELEV · Entity 77243 | CHIEF MEDICAL OFFICER | February 15, 2025 | February 19, 2025 |
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Director | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elevation Oncology, Inc.
Report date February 15, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,311 |
Ending reported balance
After 2025-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-15 · Exercise / conversion · Acquired 17,500 · Balance 17,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2025-02-15 · Tax withholding · Disposed 5,189 · Balance 12,311 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2035-02-14 | Direct | 275,000 |
Reported balance
After 2025-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-15 · Grant · Acquired 275,000 · Balance 275,000 F2: The stock option vests as to 25% of the total shares on February 15, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 52,500 |
Reported balance
After 2024-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-15 · Exercise / conversion · Disposed 17,500 · Balance 52,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3: 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4: The RSUs do not expire; they either vest or are canceled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2: The stock option vests as to 25% of the total shares on February 15, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3: 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4: The RSUs do not expire; they either vest or are canceled prior to the vesting date.
OnKure Therapeutics, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06 | Direct | 22,350 |
Reported balance
After 2026-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 22,350 · Balance 22,350 F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 11, 2026 20:37 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 22,350 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001889716-26-000002 · form4-08112026_080824.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,350 Underlying: Class A Common Stock · 22,350 shares Expires 2036-08-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:25 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 7,650 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001889716-26-000001 · form4-06082026_100613.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Class A Common Stock · 7,650 shares Expires 2036-06-03 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 20:52 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 7,650 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001415889-25-015016 · form4-05302025_080515.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Class A Common Stock · 7,650 shares Expires 2035-05-27 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:25 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001415889-25-004620 · form4-02192025_040201.xml · derivative · entry 3 Jansen Valerie Malyvanh · CIK 0001889716 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-02-14 F2 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:25 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Tax withholdingCommon Stock | 5,189 | $0.67 | $3,485.45 |
DisclosureSEC source: 0001415889-25-004620 · form4-02192025_040201.xml · nonDerivative · entry 2 Jansen Valerie Malyvanh · CIK 0001889716 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,311 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:25 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004620 · form4-02192025_040201.xml · nonDerivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 23:25 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 15,300 | $0.00 Strike: $18.20 | $0.00 |
DisclosureSEC source: 0001415889-24-024917 · form4-10082024_111035.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Class A Common Stock · 15,300 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:02 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantRestricted Stock Unit · Derivative | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004403 · form4-02202024_100233.xml · derivative · entry 2 Jansen Valerie Malyvanh · CIK 0001889716 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs vest on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:02 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001415889-24-004403 · form4-02202024_100233.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2034-02-14 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 15, 2024 Filed Feb 19, 2025 21:25 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Exercise / conversionRestricted Stock Unit · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004620 · form4-02192025_040201.xml · derivative · entry 4 Jansen Valerie Malyvanh · CIK 0001889716 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:29 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001415889-23-002771 · form4-02172023_090226.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:30 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-23-000730 · form4-01102023_090133.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vested as to 25% of the total shares on January 6, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 01:09 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001209191-22-010399 · doc4.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-02-13 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 10, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date and is subject to acceleration in the event of a change in control of the Issuer. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 22:32 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $7.58 | $0.00 |
DisclosureSEC source: 0001209191-21-061296 · doc4.xml · derivative · entry 1 Jansen Valerie Malyvanh · CIK 0001889716 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-10-18 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on October 19, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.